\begin{tabular}{lccccc}
\toprule
 & \multicolumn{3}{c}{All Changes} & \multicolumn{2}{c}{Full Sample} \\
\cmidrule(lr){2-4} \cmidrule(lr){5-6}
 & Full & Founder$\to & Outsider$\to & Better CEOs & Worse CEOs \\
 & (1) & (2) & (3) & (4) & (5) \\
\midrule
TWFE (OLS on actual) & 0.0053*** & 0.0115*** & 0.0016 & 0.0596*** & -0.0468*** \\
  & (0.0007) & (0.0012) & (0.0011) & (0.0010) & (0.0009) \\
TWFE (OLS on placebo) & 0.0010*** & 0.0013*** & 0.0006*** & 0.0256*** & -0.0249*** \\
  & (0.0002) & (0.0002) & (0.0002) & (0.0002) & (0.0002) \\
ATET (debiased) & 0.0031*** & 0.0089*** & 0.0010 & 0.0266*** & -0.0178*** \\
  & (0.0008) & (0.0013) & (0.0012) & (0.0010) & (0.0009) \\
Observations & 3,361,459 & 1,567,503 & 2,603,434 & 1,648,507 & 1,712,952 \\
\bottomrule
\end{tabular}
\begin{tablenotes}[flushleft]
\footnotesize
\item \textbf{Notes:} This table compares Average Treatment Effects on the Treated (ATET) estimates 
across different samples and CEO types. TWFE refers to Two-Way Fixed Effects regressions 
with firm and year fixed effects. The naive estimator uses actual CEO transitions, 
while the placebo estimator uses randomly assigned fake transitions. The debiased 
ATET estimator uses the \texttt{xt2treatments} command with optimal weighting and 
placebo controls. Better/worse CEOs are classified based on estimated manager fixed effects. 
Standard errors are clustered by firm. Significance levels: *** p$<$0.01, ** p$<$0.05, * p$<$0.10.
\end{tablenotes}
\end{tabular}
